1 / 19

The Future of Quality of Life Assessment in Cost-Effectiveness Research

The Future of Quality of Life Assessment in Cost-Effectiveness Research. Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong Institute for studies on Personality Disorders. QoL in HTA: QALY. In the past, much criticism. Cohen CB.

doria
Télécharger la présentation

The Future of Quality of Life Assessment in Cost-Effectiveness Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong Institute for studies on Personality Disorders

  2. QoL in HTA: QALY

  3. In the past, much criticism Cohen CB. Quality of life and the analogy with the Nazis. Journal of Medicine and Philosophy 8: 113-35, 1983.

  4. Criticism remains ….the strictly fascist essence of those QALYs (so-called Quality-Adjusted Life Years)…

  5. But QALY rules… From 1980 till 2010: 7049 publications in PubMed

  6. There is not yet an alternative…

  7. Raad voor de Volksgezondheid en Zorg • Weight QALYs by severity of illness • QALYs determine “severity”

  8. Value based pricing • Health Secretary Andrew Lansley • Measures "will help ensure better access for patients to effective drugs and innovative treatments on the NHS" • Like RvZ • Again adding severity • Adding Innovation • QALY still at the hart of the judgment • Severity and innovation both expressedterms of QALYs

  9. Efficiency frontier • Germany • IQWiG • Still discussion • whether it is possible ‘in theory’ to make such value judgments, let alone in practice

  10. Which measure? • Questionnaires • EQ-5D • HUI • SF-6D • Direct measures • TTO • Discrete choice • SG • VAS

  11. Questionnaires • EQ-5D • Dominates health economics • Said to be insensitive • New 5 level version is on its way • SF-6D • Overtook HUI in popularity • Little support development • HUI • Little recent development • Expensive

  12. Disease specific instruments • As validation methodology becomes cheaper… • Why not validate a disease specific instrument? • The big research question • Are values valid? • Are the values the same as with HUI, SF-6D etc • Narrow scope • Values are too high • Attention bias • Differences are too big

  13. Bold-on instruments • Combine generic instruments with disease specific dimensions • “Bold-on” the disease specific dimension • Can solve the narrow scope • Absolute value level might be valid • Could avoid attention bias • Does it also avoid the attention bias?

  14. Direct measures • Used to value health states in models • TTO dominates • Discrete choice coming up • SG slips aside • VAS not in favor in health economics • WTP never more than a promise

  15. The big questions • TTO • Values below dead • Discrete choice • Is discrete choice valid within the QALY approach? • How to anchor in death – normal health scale • TTO?

  16. Care • QALY in care is disputed • But QALY is ok for big issues in care • No care = dead • QALY might not be sensitive • Care might be involve other aspects than health • For instance: does not measure autonomy • Same issues as in cure? • Disease specific instrument • Involve need and innovation

  17. Discrete choice in care • New instrument for care • ICECAP • ASCOTT • Several other initiatives • What is the relation with QALY? • Why go for another scale?

  18. Conclusion: Standardization • Questionnaires • Could merge to EQ-5D • But disease specific instruments might blur • Direct valuation • TTO seems to prevail, but not yet one methodology • Care • Just the start of development

  19. Future questionnaires • Cheap EQ-5D SF-6D HUI • Sensitive SF-6D HUI EQ-5D (3L) • Simple to use EQ-5D SF-6D HUI • Many translations SF-6D EQ-5D HUI • Many value sets EQ-5D HUI SF-6D • Will EQ-5D-5L dominate? • There must be room for more instruments…

More Related